<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/604C05CE-9345-450A-9F84-FBA51CA1BA77"><gtr:id>604C05CE-9345-450A-9F84-FBA51CA1BA77</gtr:id><gtr:name>Khon Kaen University</gtr:name><gtr:address><gtr:line1>Graduate School</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3144EE59-D9F8-4551-A359-2C0F1B96A0A2"><gtr:id>3144EE59-D9F8-4551-A359-2C0F1B96A0A2</gtr:id><gtr:name>Siriraj Medical School</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:department>Dept of Surgery and Cancer</gtr:department><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/604C05CE-9345-450A-9F84-FBA51CA1BA77"><gtr:id>604C05CE-9345-450A-9F84-FBA51CA1BA77</gtr:id><gtr:name>Khon Kaen University</gtr:name><gtr:address><gtr:line1>Graduate School</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3144EE59-D9F8-4551-A359-2C0F1B96A0A2"><gtr:id>3144EE59-D9F8-4551-A359-2C0F1B96A0A2</gtr:id><gtr:name>Siriraj Medical School</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/F58C7A0D-D2B1-4345-9AA7-AAF2CF15DF94"><gtr:id>F58C7A0D-D2B1-4345-9AA7-AAF2CF15DF94</gtr:id><gtr:firstName>Kanlayanee</gtr:firstName><gtr:surname>Sawanyawisuth</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/0818198A-0317-40F5-8FFA-DE0A437DC047"><gtr:id>0818198A-0317-40F5-8FFA-DE0A437DC047</gtr:id><gtr:firstName>Chaisiri</gtr:firstName><gtr:surname>Wongkham</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/D7704561-F80F-4408-979B-FFD009511219"><gtr:id>D7704561-F80F-4408-979B-FFD009511219</gtr:id><gtr:firstName>Kulthida</gtr:firstName><gtr:surname>Vaeteewoottacharn</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/F873531B-9078-46BA-BBA6-EAAE261008B2"><gtr:id>F873531B-9078-46BA-BBA6-EAAE261008B2</gtr:id><gtr:firstName>WUNCHANA</gtr:firstName><gtr:surname>SEUBWAI</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/9B4B8222-8C76-4802-BCF8-316E81437DA9"><gtr:id>9B4B8222-8C76-4802-BCF8-316E81437DA9</gtr:id><gtr:firstName>Raynoo</gtr:firstName><gtr:surname>Thanan</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/B07259C9-AB6A-45FA-8465-F500CE28328C"><gtr:id>B07259C9-AB6A-45FA-8465-F500CE28328C</gtr:id><gtr:firstName>Sopit</gtr:firstName><gtr:surname>Wongkham</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/9D1454F0-DC38-49CA-9F08-66F1C6C1CA87"><gtr:id>9D1454F0-DC38-49CA-9F08-66F1C6C1CA87</gtr:id><gtr:firstName>Chawalit</gtr:firstName><gtr:surname>Pairojkul</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/6BCA85BF-27C5-4CB9-88C5-0D1113CB70E1"><gtr:id>6BCA85BF-27C5-4CB9-88C5-0D1113CB70E1</gtr:id><gtr:firstName>Somchai</gtr:firstName><gtr:surname>Pinlaor</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/AD73E809-7AF4-495D-B502-15063FCC7D2B"><gtr:id>AD73E809-7AF4-495D-B502-15063FCC7D2B</gtr:id><gtr:firstName>Ake</gtr:firstName><gtr:surname>PugKhem</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/B13395DB-79C1-4870-89DA-048C9DE66592"><gtr:id>B13395DB-79C1-4870-89DA-048C9DE66592</gtr:id><gtr:firstName>Vor</gtr:firstName><gtr:surname>Luvira</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/9B616818-ABF2-4DF9-958B-E35413BA8B8E"><gtr:id>9B616818-ABF2-4DF9-958B-E35413BA8B8E</gtr:id><gtr:firstName>Eric</gtr:firstName><gtr:otherNames>W-F</gtr:otherNames><gtr:surname>Lam</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/26D62A1B-EF3C-4842-92A6-F74181528226"><gtr:id>26D62A1B-EF3C-4842-92A6-F74181528226</gtr:id><gtr:firstName>Yaovalux</gtr:firstName><gtr:surname>Chamgramol</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/DCFEABEA-9916-406A-A019-FA51E4733094"><gtr:id>DCFEABEA-9916-406A-A019-FA51E4733094</gtr:id><gtr:firstName>Sakda</gtr:firstName><gtr:surname>Waraasawapati</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FN012097%2F1"><gtr:id>36566BCF-E61A-4761-AC69-47E54FF22564</gtr:id><gtr:title>Targeting the FOXM1 signature for early diagnosis and treatment in cholangiocarcinoma</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/N012097/1</gtr:grantReference><gtr:abstractText>Cholangiocarcinoma (CCA) is rare cancer of the intrahepatic and extra hepatic bile ducts. High incidences of CCA are clustered in the Greater Mekong sub-region, particularly in the northeast of Thailand. Relatively little is known about the cause of CCA, and the treatment options are limited because of late diagnosis. Researching for early diagnosis and effective treatment is an urgent need to prevent the loss from this cancer. Accumulating evidence indicates that the Forkhead box M1 (FOXM1) transcription factor has a key role in tumour initiation, progression, metastasis, angiogenesis and drug sensitivity. A previous gene array study in Thai CCA patient tissues has revealed that FOXM1 and its downstream targets as genes upregulated in almost all CCA cases. We hypothesise that FOXM1 plays a key role in CCA initiation, development and drug resistance. We aim to identify the critical FOXM1 gene transcription signatures involved in CCA tumorigenesis, progression and drug sensitivity. This will not only help to identify reliable biomarkers for early diagnosis and for predicting disease relapse but also aid the design of targeted therapies and strategies to overcome drug resistance in CCA. This joint project will also strengthen the collaborations between ICL and KKU, and promote the career development of junior researchers from both institutes.</gtr:abstractText><gtr:technicalSummary>We will study the regulation and role of FOXM1 and its downstream targets in the cholagiocarcinoma (CCA) initiation, progression and drug resistance using the zebrafish, mouse and human in vivo models as well as CCA cell lines. This study will identify key FOXM1 expression signatures essential for CCA tumorigenesis, metastasis, angiogenesis and the development of drug resistance. The proposed project consists of 4 overlapping objectives (1-4).
In objective 1, we will identify and characterize the putative FOXM1 signature genes in CCA cell lines using proliferation, clonogenic, Western blot and RT-qPCR analyses. We will then confirm these putative genes as FOXM1 downstream targets in CCA and in response to chemotherapy treatment using siRNA to selectively silence FOXM1 in drug sensitive and resistant CCA lines cells. We will also confirm these results and uncover novel FOXM1 targets by studying the mRNA and miRNA expression using microarrays.
In objective 2, the role and regulation of FOXM1 and its targets during cholangiocarcinogenesis will be confirmed in an in vivo model of liver fluke infection by immunohistochemistry staining. The role and expression of the FOXM1 signatures in CCA angiogenesis and metastasis will be examined in in vivo systems, including a novel zebrafish embryo model. The function of the FOXM1 signature in drug resistance will also be tested in CCA cell lines.
In objective 3, we will attempt to identify the components of the FOXM1 gene signature/signalling network that can be targeted to enhance cell death and senescence and to overcome drug resistance using CCA cell lines. 
In objective 4, the findings from the in vitro and in vivo studies will then be validated samples from CCA patients.
It is anticipated these studies will identify key FOXM1 gene expression signatures that are important for CCA initiation, progression and drug resistance and help to uncover crucial early diagnostic markers and therapeutic targets for CCA.</gtr:technicalSummary><gtr:potentialImpactText>FOXM1 has been implicated in cholagiocarcinoma (CCA) initiation, progression and the development of chemotherapy resistance. This study will unveil FOXM1 downstream expression signatures and help to identify crucial prognostic markers and therapeutic targets for CCA. This project will directly benefit the CCA patients and the communities that are at risk of contracting liver fluke and CCA. This project will improve CCA survival and help to relieve the health, economic and societal burden of the CCA affected communities as well as the Thai population. In addition, this project will also generate useful hypothesis, reagents, and techniques relevant for CCA researchers. A wider circle of researchers who are investigating the function and regulation of forkhead transcription factors and the potent oncogenic transcription factor FOXM1 will gain from the knowledge and information generated from this project. 
The proposed work on CCA metastasis and angiogenesis using &amp;lt; 5 day zebrafish embryos will aid the development of new 3Rs approaches and technologies that facilitates the Replacement, Refinement and Reduction of Animals in Research (NC3Rs). Particularly for scientists researching into angiogenesis and metastasis, this project will help to establish novel in vivo models, which are more economical and ethical, with a very short generation time. 
This study and its finding will benefit the KKU Co-Is, who are integral members of the Liver Fluke and CCA Research Centre, whose aims are: 1) to research into the prevention, diagnosis and treatment of CAA; 2) to facilitate local authority in district and local communities in education for prevention of liver fluke infection and CCA; 3) to build CCA research capability. As part of this programme, junior researchers from KKU will also gain from research visits and placements at ICL. They will be exposed to cutting edge technology and stimulating research environment at ICL. They will develop expertise in cancer and molecular biology as well as communication skills and research networks, which will aid their career development. High impact 'open access' publications from the joint project will also help to attract and recruit future scientists and collaborators to KKU and the Liver Fluke and CCA Research Centre to ensure that their future sustainable research capability.</gtr:potentialImpactText><gtr:fund><gtr:end>2019-01-13</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2016-01-14</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>353740</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Khon Kaen University</gtr:collaboratingOrganisation><gtr:country>Thailand, Kingdom of</gtr:country><gtr:description>Role of FOXM1 in CCA drug resistance</gtr:description><gtr:id>8A5853AA-8840-48C3-A5FE-69B524AA7E1C</gtr:id><gtr:impact>Hosting a Newton Fund/RGJ student from KKU (Kitti Intuyod ) for 1 year from 12/15-12/16.
Publications pending.</gtr:impact><gtr:outcomeId>58c6bb2f4ce2b6.05188840-1</gtr:outcomeId><gtr:partnerContribution>Collaborative research on the role of FOXM1 in CCA drug resistance</gtr:partnerContribution><gtr:piContribution>Collaborative research on the role of FOXM1 in CCA drug resistance
Hosting a Newton Fund/RGJ student for 1 year from 12/15-12/16.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Siriraj Medical School</gtr:collaboratingOrganisation><gtr:country>Thailand, Kingdom of</gtr:country><gtr:description>Functional Role if interaction between FOXO3 and cyclin D1 in senescence</gtr:description><gtr:id>AE81BC82-FB57-4C75-96FD-1C12EABEF3EA</gtr:id><gtr:impact>Pending publications</gtr:impact><gtr:outcomeId>58c6b4f67d94c0.73261066-1</gtr:outcomeId><gtr:partnerContribution>PI.
Interaction and functional experiments on the the interaction between FOXO3 and cyclin D1</gtr:partnerContribution><gtr:piContribution>Reagents to study the interaction between FOXO3 and cyclin D1 in senescence</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Siriraj Medical School</gtr:collaboratingOrganisation><gtr:country>Thailand, Kingdom of</gtr:country><gtr:description>Single-cell FoxO3a/FoxM1 dynamics and their roles on cancer therapeutic resistance</gtr:description><gtr:id>BDC54C00-A27C-4B6A-B441-60321CCABAC1</gtr:id><gtr:impact>Pending publications.
Thailand TRF Grant for New Researcher
Project title: Single-cell FoxO3a/FoxM1 dynamics and their roles on cancer therapeutic resistance
Project duration: 2 years 
Total budget: 600,000 Baht
Principal investigator / Department / Faculty / Institute
Somponnat Sampattavanich
Department of Pharmacology
Faculty of Medicine Siriraj Hospital
Mahidol University</gtr:impact><gtr:outcomeId>58c6b40dcf3069.15582053-1</gtr:outcomeId><gtr:partnerContribution>Project leader: Role and Regulation of FOXO3 and FOXM1 in single cancer cells.</gtr:partnerContribution><gtr:piContribution>Role and Regulation of FOXO3 and FOXM1 in single cancer cells.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Meetings with Director, clinicians  and staff of the Khon Kaen Liver Fluke Centre to explain and report work carried out by the MRC grant</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>17DFE8E7-03E0-4BBA-A8F8-C9B017D17672</gtr:id><gtr:impact>Meetings with Director, clinicians and staff of the Khon Kaen Liver Fluke Centre to explain and report work carried out by the MRC grant. This is the organisation which support CCA research and education in Thailand.</gtr:impact><gtr:outcomeId>58c6bd738b8c90.38881518</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Study participants or study members</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Established a CCA xenograft system in zebrafish embryo model.</gtr:description><gtr:id>BF452E6A-A158-46E7-BD74-3323FD2D5D95</gtr:id><gtr:impact>Hitherto, the work on cancer metastasis and angiogenesis has relied primarily on in vivo animal models. The proposed work on CCA metastasis and angiogenesis using &amp;lt; 5 day zebrafish embryos will aid the development of new 3Rs approaches and technologies that facilitates the Replacement, Refinement and Reduction of Animals in Research (NC3Rs). This approach avoids the use of animals defined as 'protected' under the Animals (Scientific Procedures) Act 1986, amended 2012 (ASPA) in research and also improves animal welfare by minimizing pain, and in this way, addresses societal concerns about animal research. The '3Rs' is one of the strategic aims of MRC and other research councils. The information on the zebrafish work will be disseminated through publications in high impact Journals, MRC and the public media (after liasing with ICL and MRC), scientific meetings and public engagement workshops. This will help to change future research models for angiogenesis and metastasis.</gtr:impact><gtr:outcomeId>58c6c09373bb56.34884046</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Study the role of FOXM1 in CCA angiogenesis and metastasis</gtr:title><gtr:type>Model of mechanisms or symptoms - non-mammalian in vivo</gtr:type><gtr:yearFirstProvided>2017</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>DBFDFC60-5C11-44E2-B4A0-2F65450BDA53</gtr:id><gtr:title>Glycolysis gatekeeper PDK1 reprograms breast cancer stem cells under hypoxia.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7e92a1c401ba274e42c8af7d630f6278"><gtr:id>7e92a1c401ba274e42c8af7d630f6278</gtr:id><gtr:otherNames>Peng F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>5aa665891edc15.46891321</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>77A8888C-ACFB-4C28-82E8-AF853FFF95DB</gtr:id><gtr:title>RNF168 cooperates with RNF8 to mediate FOXM1 ubiquitination and degradation in breast cancer epirubicin treatment.</gtr:title><gtr:parentPublicationTitle>Oncogenesis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1b4481e5cca2fe05db6622a4ef6891c3"><gtr:id>1b4481e5cca2fe05db6622a4ef6891c3</gtr:id><gtr:otherNames>Kongsema M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2157-9024</gtr:issn><gtr:outcomeId>58c6ac6a5dfdd0.25592800</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5F94DDC4-1B9F-4B83-8B69-EE43E49459E4</gtr:id><gtr:title>FOXD3 controls pluripotency through modulating enhancer activity.</gtr:title><gtr:parentPublicationTitle>Stem cell investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/52f173823b5f0cda2bb9709d6976556d"><gtr:id>52f173823b5f0cda2bb9709d6976556d</gtr:id><gtr:otherNames>Yong JS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2306-9759</gtr:issn><gtr:outcomeId>58c6ac663e4d68.09969075</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>42396EA3-165D-4EF7-BF82-DC48E6A7B823</gtr:id><gtr:title>Exogenous FABP4 increases breast cancer cell proliferation and activates the expression of fatty acid transport proteins.</gtr:title><gtr:parentPublicationTitle>Molecular carcinogenesis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/728168557f7065a72b2b3e6630871c21"><gtr:id>728168557f7065a72b2b3e6630871c21</gtr:id><gtr:otherNames>Guaita-Esteruelas S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0899-1987</gtr:issn><gtr:outcomeId>58c6ac64636898.52827233</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BCE15D63-29C0-4406-958C-1A108960B675</gtr:id><gtr:title>Aurora kinase A regulates Survivin stability through targeting FBXL7 in gastric cancer drug resistance and prognosis.</gtr:title><gtr:parentPublicationTitle>Oncogenesis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c1de65fc5d5062e53e410c5bdffe3581"><gtr:id>c1de65fc5d5062e53e410c5bdffe3581</gtr:id><gtr:otherNames>Kamran M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2157-9024</gtr:issn><gtr:outcomeId>58c2d116d540a0.90220402</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9B49D869-95FC-4C4D-AA15-8ECCFA858154</gtr:id><gtr:title>Extracellular vesicles in the tumor microenvironment: Therapeutic resistance, clinical biomarkers, and targeting strategies.</gtr:title><gtr:parentPublicationTitle>Medicinal research reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a9e0d8729620d00d88750bd5c4feb03"><gtr:id>2a9e0d8729620d00d88750bd5c4feb03</gtr:id><gtr:otherNames>Han L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0198-6325</gtr:issn><gtr:outcomeId>5a2fd32e609420.00014920</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AF8472E1-0ECF-4D3E-9642-DEFA6E6129FE</gtr:id><gtr:title>11a-N-Tosyl-5-deoxi-pterocarpan, LQB-223, a novel compound with potent antineoplastic activity toward breast cancer cells with different phenotypes.</gtr:title><gtr:parentPublicationTitle>Journal of cancer research and clinical oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b6a2bc7a131a57e91d5c5b084ef07368"><gtr:id>b6a2bc7a131a57e91d5c5b084ef07368</gtr:id><gtr:otherNames>Lemos LG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0171-5216</gtr:issn><gtr:outcomeId>58c6ac685aec61.52091640</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1236C4D8-1DBA-4436-AB31-ACE94CCCCD01</gtr:id><gtr:title>Multifaceted link between metabolism and cancer.</gtr:title><gtr:parentPublicationTitle>Molecular and cellular endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0187561490e9e1b2a7cf2e692a392fe3"><gtr:id>0187561490e9e1b2a7cf2e692a392fe3</gtr:id><gtr:otherNames>Saavedra-Garc?a P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0303-7207</gtr:issn><gtr:outcomeId>5aa666e57c8060.11574492</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CDB0EBF9-0F49-4EFD-AA9D-9774E9DDA05A</gtr:id><gtr:title>Insights into a Critical Role of the FOXO3a-FOXM1 Axis in DNA Damage Response and Genotoxic Drug Resistance.</gtr:title><gtr:parentPublicationTitle>Current drug targets</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/63d9c3cdab19d00e3c248a38e47bd973"><gtr:id>63d9c3cdab19d00e3c248a38e47bd973</gtr:id><gtr:otherNames>Nestal de Moraes G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1389-4501</gtr:issn><gtr:outcomeId>58c6ac64103913.65966428</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E4C276F3-E664-4E2E-A6C3-03E89265E701</gtr:id><gtr:title>p62/SQSTM1 interacts with vimentin to enhance breast cancer metastasis.</gtr:title><gtr:parentPublicationTitle>Carcinogenesis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7d69e18214ac2ca4713be9f6e2ec4738"><gtr:id>7d69e18214ac2ca4713be9f6e2ec4738</gtr:id><gtr:otherNames>Li SS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0143-3334</gtr:issn><gtr:outcomeId>5a578be2e7f2b3.63959419</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>83F44DB8-B35A-4162-88AA-E4BFA550BFD6</gtr:id><gtr:title>Metabolomics reveals novel blood plasma biomarkers associated to the BRCA1-mutated phenotype of human breast cancer.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/490a9417347b3251f4500f7822144230"><gtr:id>490a9417347b3251f4500f7822144230</gtr:id><gtr:otherNames>Roig B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5a578bde78b8c3.86880803</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6B3ED0D6-95B7-4AD5-885D-2EA78C27A96D</gtr:id><gtr:title>p62/SQSTM1 enhances breast cancer stem-like properties by stabilizing MYC mRNA.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5cb028cae89f30dc9ca9ad34d4e7d08f"><gtr:id>5cb028cae89f30dc9ca9ad34d4e7d08f</gtr:id><gtr:otherNames>Xu LZ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>58c6ac6700cbc6.53362174</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>52BDCF01-1803-4430-9AD9-0CA851F478A8</gtr:id><gtr:title>Glycolysis gatekeeper PDK1 reprograms breast cancer stem cells under hypoxia.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7e92a1c401ba274e42c8af7d630f6278"><gtr:id>7e92a1c401ba274e42c8af7d630f6278</gtr:id><gtr:otherNames>Peng F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>5a578bcd40dec4.66870247</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A70D3B1B-0F3F-494E-8523-56E4CC9A0C15</gtr:id><gtr:title>FOXM1 recruits nuclear Aurora kinase A to participate in a positive feedback loop essential for the self-renewal of breast cancer stem cells.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/70bcff386567f61b027baa4a3fd63e6d"><gtr:id>70bcff386567f61b027baa4a3fd63e6d</gtr:id><gtr:otherNames>Yang N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>58c2d117527835.28735576</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>06BC1F42-E423-4BC7-87E4-0366BA79CF05</gtr:id><gtr:title>Insights into a Critical Role of the FOXO3a-FOXM1 Axis in DNA Damage Response and Genotoxic Drug Resistance</gtr:title><gtr:parentPublicationTitle>Current Drug Targets</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/63d9c3cdab19d00e3c248a38e47bd973"><gtr:id>63d9c3cdab19d00e3c248a38e47bd973</gtr:id><gtr:otherNames>Nestal de Moraes G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>5a6eef2d0d7469.08640462</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1373C76A-D486-4A78-8A41-E869C570D871</gtr:id><gtr:title>Nuclear AURKA acquires kinase-independent transactivating function to enhance breast cancer stem cell phenotype.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/43f9e7f9e49e9c4cfbc481700a495dad"><gtr:id>43f9e7f9e49e9c4cfbc481700a495dad</gtr:id><gtr:otherNames>Zheng F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>58c6ac6a2199a8.56892462</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5BEBB0ED-9958-4C16-83E0-FE598A2FD7B1</gtr:id><gtr:title>Dysfunction of the WT1-MEG3 signaling promotes AML leukemogenesis via p53-dependent and -independent pathways.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/367ee7d8ad100ecb9b862984e77fa34b"><gtr:id>367ee7d8ad100ecb9b862984e77fa34b</gtr:id><gtr:otherNames>Lyu Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn><gtr:outcomeId>5aa6666c1b37b7.36029074</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0461F458-1262-4295-9865-85EA0E044E4A</gtr:id><gtr:title>BQ323636.1, a Novel Splice Variant to NCOR2, as a Predictor for Tamoxifen Resistant Breast Cancer.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f19c1d17a8e80924471de73ee5c11b4f"><gtr:id>f19c1d17a8e80924471de73ee5c11b4f</gtr:id><gtr:otherNames>Gong C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>5a995ed18a2f29.70912697</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>95D4F071-B8AB-4190-AEA4-2BE0BBAE1EEC</gtr:id><gtr:title>Erratum to: In Vitro Methods for Studying the Mechanisms of Resistance to DNA-Damaging Therapeutic Drugs.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9c609574c2a44d10ae29c57fe294190a"><gtr:id>9c609574c2a44d10ae29c57fe294190a</gtr:id><gtr:otherNames>Khongkow P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>58c6ac67b94e58.95296983</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D2AC73A5-83E9-438C-BB25-A3FD3C7C2C9E</gtr:id><gtr:title>The FOXO3-FOXM1 axis: A key cancer drug target and a modulator of cancer drug resistance.</gtr:title><gtr:parentPublicationTitle>Seminars in cancer biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4c9327921cd3a4c26e00a5f3914d0bdd"><gtr:id>4c9327921cd3a4c26e00a5f3914d0bdd</gtr:id><gtr:otherNames>Yao S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1044-579X</gtr:issn><gtr:outcomeId>5aa665ed7b5a23.59445086</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C656ADAA-F670-4274-9877-A4976FC158D4</gtr:id><gtr:title>In Vitro Methods for Studying the Mechanisms of Resistance to DNA-Damaging Therapeutic Drugs.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9c609574c2a44d10ae29c57fe294190a"><gtr:id>9c609574c2a44d10ae29c57fe294190a</gtr:id><gtr:otherNames>Khongkow P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>58c6ac68245a13.43362092</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5B9724DA-F4A5-45D2-BBC0-33643F905EB9</gtr:id><gtr:title>H19/let-7/LIN28 reciprocal negative regulatory circuit promotes breast cancer stem cell maintenance.</gtr:title><gtr:parentPublicationTitle>Cell death &amp; disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7e92a1c401ba274e42c8af7d630f6278"><gtr:id>7e92a1c401ba274e42c8af7d630f6278</gtr:id><gtr:otherNames>Peng F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>58c6ac673ba632.31636083</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E5CB5F6A-22DE-42E1-B2EC-97B43D915E4B</gtr:id><gtr:title>Unravelling the role of fatty acid metabolism in cancer through the FOXO3-FOXM1 axis.</gtr:title><gtr:parentPublicationTitle>Molecular and cellular endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0187561490e9e1b2a7cf2e692a392fe3"><gtr:id>0187561490e9e1b2a7cf2e692a392fe3</gtr:id><gtr:otherNames>Saavedra-Garc?a P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0303-7207</gtr:issn><gtr:outcomeId>58c6add16d0fa4.36413098</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1D6D12CD-E894-4A6A-8194-6D5DECD60592</gtr:id><gtr:title>Paclitaxel targets FOXM1 to regulate KIF20A in mitotic catastrophe and breast cancer paclitaxel resistance.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9c609574c2a44d10ae29c57fe294190a"><gtr:id>9c609574c2a44d10ae29c57fe294190a</gtr:id><gtr:otherNames>Khongkow P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>58c6ac65ea5a64.59929698</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AF67E72C-C329-4019-88B0-D8B357BAB69D</gtr:id><gtr:title>Metabolomic characterisation of the effects of oncogenic PIK3CA transformation in a breast epithelial cell line.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b120a1f348ecc224e0db1b8c5ba522cc"><gtr:id>b120a1f348ecc224e0db1b8c5ba522cc</gtr:id><gtr:otherNames>Lau CE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5a578bd99fac02.21815656</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7A75F440-E135-477C-8146-E0A0DCF2E784</gtr:id><gtr:title>Dataset of the human homologues and orthologues of lipid-metabolic genes identified as DAF-16 targets their roles in lipid and energy metabolism.</gtr:title><gtr:parentPublicationTitle>Data in brief</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7086a0aff16d7a54d1b04da5190a8849"><gtr:id>7086a0aff16d7a54d1b04da5190a8849</gtr:id><gtr:otherNames>Fan LY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2352-3409</gtr:issn><gtr:outcomeId>5a578ba52dd2f0.01898209</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1020847B-8933-4D30-823C-A08D207F3AEA</gtr:id><gtr:title>Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer.</gtr:title><gtr:parentPublicationTitle>Breast cancer research and treatment</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1a0b9c09a29d65bdd7a60852150465b7"><gtr:id>1a0b9c09a29d65bdd7a60852150465b7</gtr:id><gtr:otherNames>Asaduzzaman M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0167-6806</gtr:issn><gtr:outcomeId>5aa666e5e25161.43431058</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F8C497A0-F9FA-4989-97C4-198F7BE9D0A4</gtr:id><gtr:title>BRCA1 positively regulates FOXO3 expression by restricting FOXO3 gene methylation and epigenetic silencing through targeting EZH2 in breast cancer.</gtr:title><gtr:parentPublicationTitle>Oncogenesis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f19c1d17a8e80924471de73ee5c11b4f"><gtr:id>f19c1d17a8e80924471de73ee5c11b4f</gtr:id><gtr:otherNames>Gong C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2157-9024</gtr:issn><gtr:outcomeId>58c6ac69904582.44968516</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>10A75B60-B632-4920-8DB2-685948E2C37F</gtr:id><gtr:title>ER stress and cancer: The FOXO forkhead transcription factor link.</gtr:title><gtr:parentPublicationTitle>Molecular and cellular endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4db0226b72d89ca4ccf4ad1018f9532f"><gtr:id>4db0226b72d89ca4ccf4ad1018f9532f</gtr:id><gtr:otherNames>Alasiri G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0303-7207</gtr:issn><gtr:outcomeId>5a2fd341a10425.76054333</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/N012097/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes><gtr:rcukProgramme><gtr:id>C11BDEA9-7D9D-4728-B6A9-31032921B328</gtr:id><gtr:text>Newton</gtr:text></gtr:rcukProgramme></gtr:rcukProgrammes></gtr:project></gtr:projectComposition></gtr:projectOverview>